Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Flow-mediated dilation

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    35 result(s) found for: Flow-mediated dilation. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2013-002266-40 Sponsor Protocol Number: CAIN457ADE02 Start Date*: 2013-12-09
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A randomized, double-blind, placebo-controlled, multicenter, exploratory evaluation of surrogate markers of cardiovascular risk in patients with active chronic plaque-type psoriasis treated for 52 ...
    Medical condition: active chronic plaque-type psoriasis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-004012-78 Sponsor Protocol Number: TCW-05/02 Start Date*: 2005-12-16
    Sponsor Name:Medical University of Graz
    Full Title: Effects of acarbose on endothelial function, platelet activity, insulin sensitivity and glucose control in subjects with coronary artery disease and new onset type-II diabetes.
    Medical condition: Patients with angiographically verified coronary artery disease and newly detected type-2 diabetes.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2015-004164-11 Sponsor Protocol Number: DAPA-BP Start Date*: 2015-11-19
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
    Full Title: Effect of dapagliflozin on flow-mediated dilation and blood pressure (DAPA-BP): a phase III, randomized, open-label, parallel group study in hypertensive patients with controlled type 2 diabetes
    Medical condition: Arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10020775 Hypertension arterial LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005343-27 Sponsor Protocol Number: Metformin-FMD001 Start Date*: 2012-01-27
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: Can metformin prevent endothelial ischemia and reperfusion injury? The Metformin-FMD trial.
    Medical condition: ischemia and reperfusion injury endothelial dysfunction
    Disease: Version SOC Term Classification Code Term Level
    14.1 10047065 - Vascular disorders 10063837 Reperfusion injury PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-004992-37 Sponsor Protocol Number: 2012/1419 Start Date*: 2013-02-25
    Sponsor Name:South-Eastern Norway Regional Health Authority [...]
    1. South-Eastern Norway Regional Health Authority
    2. Oslo University Hospital Rikshospitalet
    Full Title: The effects of n-3 polyunsaturated fatty acids on glomerular filtration rate, proteinuria, fibrosis and inflammation in the kidney transplant and cardiovascular risk markers in kidney transplant re...
    Medical condition: Renal transplantation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-014831-18 Sponsor Protocol Number: fmd/01 Start Date*: 2009-09-25
    Sponsor Name:RUNMC
    Full Title: Short term statin treatment and endothelial dysfunction due to ischemia and reperfusion injury
    Medical condition: ischemia and reperfusion injury endothelial dysfunction
    Disease: Version SOC Term Classification Code Term Level
    12.0 10063837 Reperfusion injury LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000328-85 Sponsor Protocol Number: FINNHT1 Start Date*: 2017-05-18
    Sponsor Name:Helsinki University Hospital, Obstetrics and Gynecology
    Full Title: Randomized comparative trial between abrupt and tapered mode of discontinuation of longterm hormone therapy: Impact on endothelial function, recurrence of vasomotor symptoms and quality of life
    Medical condition: We will assess the effects of hormone therapy termination on endothelial function using biophysical (flow-mediated dilation, peripheral artery tonometry) and biochemical markers. We will compare th...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038604 - Reproductive system and breast disorders 10027311 Menopause flushing LLT
    20.0 10041244 - Social circumstances 10076936 Impaired quality of life PT
    20.1 10038604 - Reproductive system and breast disorders 10027301 Menopausal hot flushes LLT
    20.1 10022891 - Investigations 10060858 Cardiovascular function test PT
    20.0 10041244 - Social circumstances 10027308 Menopause PT
    16.1 10038604 - Reproductive system and breast disorders 10027309 Menopause and related conditions HLGT
    20.0 10007541 - Cardiac disorders 10007649 Cardiovascular disorder PT
    20.0 10041244 - Social circumstances 10051775 Postmenopause PT
    20.0 10047065 - Vascular disorders 10048554 Endothelial dysfunction PT
    Population Age: Adults Gender: Female
    Trial protocol: FI (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-001688-74 Sponsor Protocol Number: WX18694 Start Date*: 2005-09-22
    Sponsor Name:Guy's & St Thomas' NHS Foundation Trust
    Full Title: A prospective, randomized, double-blind, placebo controlled trial evaluating the effects of Mycophenolate Mofetil (MMF) on 'surrogate markers' for atherosclerosis in female patients with systemic l...
    Medical condition: Atherosclerosis in patients with Systemic Lupus Erythematosis
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-003583-31 Sponsor Protocol Number: BCBe/05/Neb-Pao/088 Start Date*: 2006-04-12
    Sponsor Name:Berlin-Chemie AG
    Full Title: NEBIVOLOL OR METOPROLOL IN ARTERIAL OCCLUSIVE DISEASE A DOUBLE-BLIND, RANDOMISED CLINICAL Deutscher Titel: Nebivolol im Vergleich zu Metoprolol bei peripherer arterieller Verschlusskrankheit Eine ...
    Medical condition: Intermittent claudication (peripheral arterial disease) Fontaine’s stage II Deutsch: Periphere arterielle Verschlusskrankheit, Fontaine Staidum II
    Disease: Version SOC Term Classification Code Term Level
    8.0 10062585 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-003908-61 Sponsor Protocol Number: Vasc-UMCU-10B Start Date*: 2008-12-09
    Sponsor Name:University Medical Center Utrecht
    Full Title: A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, 2-PERIOD, CROSSOVER STUDY TO COMPARE THE EFFECTS OF EZETIMIBE/SIMVASTATIN (10 MG/10 MG) COMBINATION TABLET VERSUS SIMVASTATIN 80 MG TABLET ON POSTPRANDIAL A...
    Medical condition: Metabolic syndrome as defined by the ATP III criteria
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052066 Metabolic syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-017011-16 Sponsor Protocol Number: 0000000000000000000 Start Date*: 2011-06-16
    Sponsor Name:University Federico II
    Full Title: Treatment of the low IGF-1 syndrome associated with Chronic Heart Failure: A Randomized, Placebo-Controlled, Double-Blind Study
    Medical condition: Low serum IGF-I and GH deficiency in patients with congestive heart failure
    Disease:
    Population Age: Adults, Elderly Gender:
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004370-55 Sponsor Protocol Number: 2007-004370-55 Start Date*: 2007-12-14
    Sponsor Name:AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA' GRANDA (A.O. DI RILIEVO NAZIONALE)
    Full Title: Effects of tetrahydrobiopterin (6R-BH4) on flow-mediated dilation in CADASIL patients: a randomised controlled trial
    Medical condition: CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy), is a rare autosomal dominant disorder characterized by recurrent strokes starting in mid-adulth...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008804 Chromosomal abnormalities and abnormal gene carriers HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-018639-17 Sponsor Protocol Number: UR2010MSyn Start Date*: 2010-06-29
    Sponsor Name:University Hospital Erlangen
    Full Title: Prospective and open label study with blind end point evaluation on the effect of mineralcorticoid receptor inhibition on endothelial function of the micro- and macrovasculature in patient with met...
    Medical condition: Metabolic syndrome
    Disease: Version SOC Term Classification Code Term Level
    12.1 10052066 Metabolic syndrome LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-005175-18 Sponsor Protocol Number: 151610/06 Start Date*: 2007-09-27
    Sponsor Name:Dpt. of Internal Medicine, Medical University of Innsbruck
    Full Title: Influence of insulin Levemir on endothelial function in type 2 diabetes mellitus. A prospective case-control study.
    Medical condition: Patients with known history of type 2 Diabetes Mellitus longer than 6 months, who were treated by diet in combination with oral antidiabetic drugs (OADs) are to be included in the study.
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001240-64 Sponsor Protocol Number: mz-02 Start Date*: 2013-07-09
    Sponsor Name:Bispebjerg Hospital
    Full Title: Effect of intact GLP-1 (7-36) and GLP-1 metabolite (9-36) on coronary and peripheral vascular function in adults
    Medical condition: Microvascular myocardial dysfunction
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004860 10012654 Diabetic complications cardiovascular HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002153-35 Sponsor Protocol Number: GAP Start Date*: 2015-09-10
    Sponsor Name:Bispebjerg University Hospital
    Full Title: Effect of Glucagon-like peptide-1 stimulation on coronary microvascular dysfunction in women with angina pectoris and no obstructive stenosis of major coronary vessels
    Medical condition: Patients with angina pectoris and coronary microvascular dysfunction without significant stenosis og major coronary vessels
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004849 10065566 Microvascular angina LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2014-004490-17 Sponsor Protocol Number: 72 Start Date*: 2014-12-17
    Sponsor Name:Bipebjerg University Hospital
    Full Title: Effect of ACE-Inhibition on Microvascular Function in Women with Assessed Microvascular Dysfunction and No Obstructive Coronary Artery Disease.
    Medical condition: Microvascular dysfunction/microvascular angina
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004849 10065566 Microvascular angina LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2022-003797-23 Sponsor Protocol Number: KKS-305 Start Date*: 2023-05-16
    Sponsor Name:Philipps University Marburg
    Full Title: Myeloperoxidase inhibition in patients with ischemic or non-ischemic cardiomyopathy and heart failure with reduced ejection fraction
    Medical condition: Ischemic or non-ischemic cardiomyopathy and heart failure with reduced ejection fraction. Danke
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007554 Cardiac failure PT
    27.0 10007541 - Cardiac disorders 10078289 Heart failure with reduced ejection fraction PT
    20.0 10007541 - Cardiac disorders 10055222 Non-ischemic cardiomyopathy LLT
    20.0 10007541 - Cardiac disorders 10055217 Ischemic cardiomyopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000981-12 Sponsor Protocol Number: ALIROCKS_05MAR2018_V3 Start Date*: 2018-05-11
    Sponsor Name:Medical University of Graz
    Full Title: A PILOT STUDY INVESTIGATING THE EFFECTS OF LIPID-THERAPY INTENSIFICATION WITH ALIROCUMAB ON ENDOTHELIAL FUNCTION, CAROTID ARTERIES, LIPOPROTEIN PARTICLE SUBFRACTIONS, INFLAMMATION AND POST-PRANDIAL...
    Medical condition: Primary Hypercholesterolemia in secondary prevention after an acute atherosclerotic, ischaemic cardiovascular event for patients with diagnostically confirmed coronary heart disease and / or periph...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-019977-14 Sponsor Protocol Number: CILOS-RAY2010 Start Date*: 2010-11-04
    Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA SAN MARTINO GENOVA
    Full Title: Efficacy of Cilostazol for the treatment of Raynaud’s Phenomenon in patients affected by Systemic Sclerosis
    Medical condition: Patients affected by Systemic Sclerosis with Raynaud’s Phenomenon
    Disease: Version SOC Term Classification Code Term Level
    9.1 10042953 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 03 19:53:14 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA